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A B S T R A C T   
Background and purpose: External beam radiotherapy for prostate cancer deposits incidental dose to a region 
surrounding the target volume. Previously, an association was identified between tumor control and incidental 
dose for patients treated with conventional radiotherapy. We investigated whether such an association exists for 
patients treated using intensity modulated radiotherapy (IMRT) and tighter margins. 
Materials and methods: Computed tomography scans and three-dimensional treatment planning dose distributions 
were available from the Dutch randomized HYPRO trial for 397 patients in the standard fractionation arm 
(39 × 2 Gy) and 407 patients in the hypofractionation arm (19 × 3.4 Gy), mainly delivered using online image- 
guided IMRT. Endpoint was any treatment failure within 5 years. A mapping of 3D dose distributions between 
anatomies was performed based on distance to the surface of the prostate delineation. Mean mapped dose dis-
tributions were computed for patient groups with and without failure, obtaining dose difference distributions. 
Random patient permutations were performed to derive p values and to identify relevant regions. 
Results: For high-risk patients treated in the conventional arm, higher incidental dose was significantly associated 
with a higher probability of tumor control in both univariate and multivariate analysis. The locations of the 
excess dose mainly overlapped with the position of obturator internus muscles at about 2.5 cm from the prostate 
surface. No such relationship could be established for intermediate-risk patients. 
Conclusions: An association was established between reduced treatment failure and the delivery of incidental dose 
outside the prostate for high-risk patients treated using conventionally fractionated IMRT.   
1. Introduction 
Prostate cancer is the second most frequently diagnosed cancer [1] 
and the sixth leading cause of cancer death in males worldwide [2]. 
Radiotherapy (RT) is a viable option for clinically localized prostate 
cancer [3], and can optionally target regions suspected of subclinical 
involvement with reduced dose. There might be a rationale to target 
elective regions around the prostate and around pelvic lymph nodes, 
since several studies have shown considerable rates of extra-prostatic 
disease in prostatectomy series, and lymph node involvement in 
lymph node dissection series and imaging studies. However, the clinical 
benefit of such elective fields in the primary RT setting is questioned 
since previous randomized trials in the three-dimensional conventional 
radiotherapy (3DCRT) era did not show any benefit of adding such fields 
[4,5] while at the same time these are associated with increased toxicity 
rates. 
With external beam radiotherapy, incidental dose is unavoidably 
delivered outside the target volume, potentially targeting subclinical 
disease. While improved diagnostic magnetic resonance imaging (MRI) 
and lymph node staging using prostate-specific membrane antigen 
(PSMA) positron emission tomography (PET) [6] may increase the 
detection rate of organ non-confined disease (and thus lead to a stage 
migration), no imaging technique is perfect and those patients clinically 
diagnosed with localized disease may yet suffer undetectable loco- 
regional progression. Previously a relationship was demonstrated in a 
prostate cancer patient trial population treated with 3DCRT, where dose 
delivery in the obturator region was significantly associated with 
freedom from failure [7]. A prophylactic incidental dose-response effect 
was confirmed in a randomized toxicity trial [8] where tumor control for 
high-risk patients was found to be superior for rectangular fields 
compared to 3DCRT. 
Nowadays patients are treated with high dose conformity and small 
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margins using image guided intensity modulated radiotherapy (IG- 
IMRT), and the dose at major lymph node stations is for all prostate 
cancer patients below clinically effective levels. With IG-IMRT, dose 
levels in excess of 50 Gy are typically only present within the first 3 cm 
from the surface of the delineated prostate. In the current study, we 
investigated whether a relationship between incidental dose and tumor 
control can be found in an IG-IMRT setting. To this purpose, we per-
formed a retrospective unplanned analysis of both study arms of the 
prospective HYPRO study [12] in which patients were randomized be-
tween standard fractionation and hypofractionation. 
2. Materials and methods 
2.1. Patients 
In the Dutch multi-center open-label randomized phase III trial 
‘HYPRO’, patients with histologically confirmed intermediate or high- 
risk localized prostate cancer were recruited and randomly allocated 
to either conventionally fractionated (39 × 2.0 Gy, CF) or hypo- 
fractionated (19 × 3.4 Gy, HF) radiotherapy. The HYPRO trial was 
approved by the Medical Ethics Committee of the Erasmus Medical 
Center in Rotterdam, the Netherlands (06-045). The participants pro-
vided their written informed consent to participate in this study. The 
study population and procedures have previously been described in 
detail [12]. Based on the estimated risk of seminal vesicle (SV) 
involvement [13,14], three treatment groups were defined for SV dose 
prescription. For patients in group 1 (risk of SV involvement < 10%) the 
clinical target volume was the delineated prostate only, in groups 2 and 
3 the SV were part of the clinical target volume (CTV). In group 3 (risk of 
SV involvement > 25%) these were prescribed the same dose as the 
prostate, but in group 2 the SV prescription was lowered to 70 Gy and 
54.5 Gy for CF and HF, respectively. Treatment planning CT scans with 
delineated prostate and 3D dose distributions as exported from the 
treatment planning system were available. 
Since a potential effect of extra-prostatic dose would be expected to 
correlate with the risk of organ non-confined disease, patients were 
subdivided in intermediate and high-risk subgroups. Treatment failure 
was defined as biochemical relapse [15], clinical relapse, loco-regional 
or distant relapse, or start of hormone therapy, whichever occurred 
first. All failures within 5 years were labeled as ‘failure/event’ for the 
current analyses of incidental dose correlations. 
For our analysis we considered patients with sufficient follow-up 
from the updated database [16] and available treatment planning CT 
and 3D dose distribution, at intermediate (CF: 90 patients, HF: 86 pa-
tients) and high prognostic risk (CF: 249 patients, HF: 241 patients), 
analyzing in total 666 out of the 804 patients (83%) of the total HYPRO 
study population previously available for relapse-free survival analysis. 
Relapse was defined as biochemical relapse, clinical relapse, locore-
gional or distant relapse, or start with hormonal therapy, whichever 
happened first. Biochemical relapse was defined as prostate-specific 
antigen (PSA) concentration greater than the present nadir plus 2 ng/ 
mL, without backdating. Patients who died without evidence of previous 
relapse and not because of toxic effects of treatment were censored at 
date of death. 
2.2. Dose mapping 
A dose mapping procedure was followed [7] based on the prostate 
delineation as it was used for treatment planning, and the 3D dose dis-
tribution exported form the treatment planning system. Outside the 
prostate, two points in the anatomies of different patients map to the 
same location if they have the same direction with respect to the center 
of mass of the prostate, and the same distance to the triangulated 
prostate surface. Inside the prostate delineation, the relative distance 
between center of mass and surface should correspond. To aggregate 
results and enable anatomical interpretation, the Visible Human data set 
[17] was used as anatomical template with a prostate delineation that 
was specifically generated to resemble a radiotherapy CTV, but yet to 
have a smooth surface, minimizing potential mapping artifacts. A suf-
ficiently large dose grid with 4 mm cubic voxels was constructed around 
the prostate. For a given patient the dose values at these grid locations 
were computed by trilinear interpolation at the corresponding mapped 
location in the patient’s 3D planning dose distribution. Dose differences 
by failure were computed by first evaluating the average 3D mapped 
dose distribution over the patient subgroup who had experienced 
treatment failure, minus the average dose over the failure-free patient 
subgroup. In-house developed software ‘Match42′ was used, consisting 
of C++ computational modules, a GUI built in Delphi, and a Python 
scripting layer. 
2.3. Statistical analysis 
To test for significantly different mean dose differences between 
outcome subgroups, a permutation method was used [18]. Patient per-
mutations were performed, randomly relabeling patients between the 
failure and non-failure cohorts. For each permutation a map of dose 
differences was generated. Dose differences were collected for those 
voxels which on average (over both groups) received at least 10% of the 
prescribed dose, and the 99th percentile maximum in absolute value was 
recorded (i.e. the maximum absolute difference after removing the 1% 
voxels with highest absolute difference). Repeating these permutations 
10,000 times, a cumulative histogram was constructed. For an observed 
dose difference map a global p-value was computed as the fraction of 
randomizations with a 99th percentile maximum dose difference higher 
than observed. 
Furthermore, patient permutations were performed to estimate q- 
value maps which could be thresholded to identify subsets of voxels at 
given estimated false discovery rate [19]. For each permutation a map of 
p-values was generated using a t-test per voxel, and a global null his-
togram of p-values was accumulated over the permutations. From these, 
the proportion of true null hypotheses for a given p-value cut-off was 
estimated [20], and used to translate the map of p-values for an observed 
dose difference to the corresponding q-value map. The estimated pro-
portion of falsely discovered voxels is expected to be conservative and 
robust against positive correlations between voxels (see [21] and ref-
erences therein). 
For maps with a significant difference at the permutation test 
(p < 0.05), a location was selected from a region with low q-values, and 
the dose for each patient was extracted. Using dose cut-offs chosen to be 
relevant for the observed values, Kaplan-Meier survival analyses were 
performed (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, 
Version 25.0. Armonk, NY: IBM Corp.). Also, these mapped dose values 
were added to multivariate Cox regression models which were con-
structed from established risk factors for treatment failure (T-stage, PSA, 
Gleason, adjuvant hormone therapy) which were significant at univar-
iate analysis. 
2.4. Linear-quadratic dose correction 
At intermediate dose levels outside the target area the daily dose 
levels are lower than inside the target, therefore non-linear biological 
effects depend not only on the fractionation scheme, but also on loca-
tion. To allow comparison of these effects we derived mapped dose 
distributions biologically equivalent to 2 Gy using the linear quadratic 
model assuming α/β ratios of 3 Gy and 1 Gy, and computed maps of 
mean dose and standard deviation of dose over the CF and HF patient 
groups. 
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3. Results 
3.1. Dose difference maps 
Dose difference maps around the prostate (i.e. average dose map of 
subgroup ‘no failure’ within 5 years minus average dose map of sub-
group ‘failure’), were generated for the two risk groups and separately 
for HF and CF (Fig. 1). In the intermediate-risk group positive and 
negative dose differences up to 10 Gy were observed in both the CF and 
HF arms, however the numbers of patients in these groups were rela-
tively small (N = 90 and N = 86, respectively), and these differences 
were not significant in the permutation tests. For the larger group of 
high-risk patients, only smaller dose differences were observed for the 
HF group (241 patients), which were not significant. Only for the CF arm 
the p derived from permutation (p = 0.037) was significant at the 5% 
level, and for this group mainly positive dose differences at q-values less 
than 25%, i.e. with an expected proportion of false discoveries below 
25%, were observed around the prostate in a region overlapping with 
obturator internus muscles (Fig. 2). Most prominent differences 
occurred at about 2.5 cm distance from the prostate surface where 
typically incidental dose levels of 40 Gy to 60 Gy can be found in the CF 
treatment plans. 
3.2. Adjusting for time-to-event and other variables 
Significantly different freedom from tumor progression (p < 0.01) 
was observed for the high-risk CF group using dose cutoffs of 45 Gy and 
55 Gy (Fig. 3). Table 1 shows results for univariate (UV) and multivar-
iate (MV) analysis. As expected, Gleason score and AHT had an impact 
both for CF and HF patients. When adding the extra-prostatic point dose 
values as a variable in the CF group in a time-to-event Cox regression, it 
had significant predictive power both at univariate (HR = 0.61, 
p < 0.01) and multivariate analysis (HR = 0.57, p < 0.01), indicating 
that the HR was stable and there was no confounding effect of other 
clinical variables in the dose maps. 
3.3. Fractionation effects 
For CF the high dose region was largely unaffected by fractionation 
correction, while the biologically corrected intermediate dose ranges 
became concentrated closer to the target as the relative contribution of 
the quadratic term in the linear-quadratic model was increased (Fig. 4). 
At the same time, standard deviation of the biologically corrected dose 
was somewhat increased. For the HF group the physical dose to the 
target was lower at 64 Gy, but became comparable to the CF arm after 
EQD2Gy correction with α/β = 3 Gy and superior both in- and outside the 
target when using α/β = 1 Gy. The same was observed for the standard 
deviation of the dose. 
4. Discussion 
An association was found between incidental dose around the pros-
tate and tumor control probability for high-risk patients treated with 
conventionally fractionated modern RT techniques, with a benefit for 
higher extra-prostatic dose levels. The critical incidental dose levels in 
this region were typically in the range of 40 Gy to 60 Gy, comparable to 
broadly recognized elective dose levels of 46 Gy to 50 Gy appropriate to 
target subclinical disease. 
To our knowledge no other reports of a correlation between tumor 
control and extra-prostatic dose for IMRT patients have been published. 
The reporting of increased failure rates in an IMRT trial [11] with 
intensive image guidance and reduced margins could be interpreted as a 
hint towards such an effect. An alternative interpretation could be that 
residual geometric uncertainties were underestimated. 
Treatment effects of unintentional radiation dose have been 
considered in other tumor sites. A recent study [9] demonstrated that for 
bladder cancer patients treated with conformal radiotherapy, high levels 
of incidental dose were delivered mainly to obturatorial lymph nodes, 
and these authors hypothesized this may have caused a lack of clear 
benefit in trials testing nodal irradiation. Another study [10] investi-
gated incidental dose being prophylactic for nodal relapse in lung cancer 
patients. In such cases however, disease stage and risk of nodal 
Fig. 1. Dose differences by failure mapped around the prostate in axial view with delineated structures bladder (yellow), prostate (cyan) and rectum (magenta). 
Light and dark gray lines indicate q-values of 25% and 50%, respectively. Global p-values were based on random patient permutations. 1a Intermediate-risk CF; 1b 
high-risk CF; 1c intermediate-risk HF; 1d high-risk HF. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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involvement may be quite different from those of a prostate radio-
therapy population. 
A main concern with the retrospective analysis of imaging data are 
the multiple testing issues introduced by the large numbers of voxels 
being analyzed. By extensively using permutation approaches we were 
able to derive a single p-value for a dose difference map based on the 
observed maximum difference, and we converted less-informative per- 
voxel p-values to q-values which allow a quantitative interpretation. 
This way we were able to show that observed dose differences were not 
likely purely coincidental, and we could identify the anatomical regions 
where dose differences were most prominent. However, dose values 
along an external beam direction are dependent, and patterns of varia-
tion are correlated due to symmetries in optimized radiation plans. It is 
therefore not possible to identify isolated anatomical effect regions; 
indeed, the location that was selected for point dose analysis should only 
be considered indicative for a possible effect in relevant regions. 
A significant result was only found for dose differences in the high- 
risk patient group in the conventional arm. For the smaller groups of 
Fig. 2. Axial (top) and coronal (bottom) slices through the CT set (left) and the anatomy based on cryo slices (right) of the Visible Human data set with delineated 
structures bladder (yellow), prostate (cyan) and rectum (magenta). Light and dark gray lines indicating q-values of 25% and 50% correspond to the results in Fig. 1b 
for high risk CF patients. Dose values at the location of the cyan cross at 2.5 cm from the delineated prostate were used for subsequent survival analysis and logistic 
regression. Abbreviations: bl: bladder, fm: femur, hb: hip bone, oi: obturator internus, pr: prostate, rc: rectum, sv: seminal vesicles. (For interpretation of the ref-
erences to colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 3. Kaplan Meier curves (free from tumor progression) for high risk patients in the conventional treatment arm, using 45 Gy and 55 Gy dose cut-off levels in the 
location marked with a cyan cross in Fig. 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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intermediate risk patients, the observed dose differences were of com-
parable magnitude, however as the permutation tests indicated these 
could well be the result of stochastic variation; only for a sufficiently 
large sample of patients a stable average dose distribution is to be 
expected. 
An association was not found for the subgroup receiving hypo- 
fractionated treatment. From this observation, two distinct implica-
tions can be inferred. Firstly, the non-observation in the HF arm 
strengthens the notion of a causal relation in the CF arm between the 
observed dose differences and treatment effect, i.e. the existence of an 
extra-prostatic dose-effect relation. This follows from consideration of 
the opposite, so assuming some unidentified clinical factor correlating 
both with extra-prostatic dose and with outcome. As the CF and HF 
patients were subdivided purely by randomization, various patient and 
treatment characteristics are expected to be evenly distributed; indeed, 
this is the rationale to perform a randomization. So, if such a factor 
would indirectly have led to the observed dose differences in the CF arm, 
then this factor should be expected to also have led to similar dose 
Table 1 
Cox regression based on relapse free survival at 5 yr from randomization for high risk patients in the two treatment arms. Univariately (borderline) significant clinical 
covariates were tested in multivariate models, and for the conventional patients the recorded extraprostatic dose values were optionally added.  
CF N = 249 UV MV MV 
variable HR p HR (95% CI) p HR (95% CI) p 
T-stage (3 vs. 1 2)  0.70  0.13     
Gleason (≥vs. < 8)  1.64  0.031 1.86 (1.2 3.0)  0.009 2.05 (1.3 3.3)  0.003 
PSA (>vs. ≤ 20ngml− 1)  1.20  0.4     
AHT (yes vs. no)  0.58  0.034 0.50 (0.3 1.0)  0.009 0.43 (0.3 0.7)  0.002 
Hospital (ref = largest)   0.3     
D+ (per 10 Gy)  0.61  0.001   0.57 (0.4 0.8)  <0.001  
HF N=241 UV  MV  
variable HR p HR (95% CI) p 
T-stage (3 vs. 1 2) 0.81 0.4   
Gleason (≥vs.< 8) 2.22 0.001 2.24 (1.4 3.6) 0.001 
PSA (>vs. ≤20ngml− 1) 0.94 0.8   
AHT (yes vs. no) 0.61 0.065 0.60 (0.4 1.0) 0.058 
Hospital (ref = largest)  0.9    
Fig. 4. Mean and standard deviation of dose distributions mapped around the prostate in coronal view for high-risk patients treated with conventional fractionation 
(top rows) and hypofractionation (bottom rows), using physical dose and EQD2Gy with α/β = 3 Gy and α/β = 1 Gy (columns left to right). Delineated structures are 
prostate (cyan) and rectum (magenta). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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differences in the HF arm. In other words, the reason dose differences 
were observable should be found in the difference between the 
randomization arms, which are different only in the way patients 
received radiation dose. Secondly, the linear-quadratic model with 
α/β = 3 Gy seems inappropriate to describe the mechanism that caused 
the observed dose differences. Since the EQD2Gy corrected CF and HF 
dose distributions at α/β = 3 Gy are highly similar, an extra-prostatic 
dose effect visible in one arm would also be expected to manifest in 
the other arm. This suggests the extra-prostatic dose effect requires a 
much lower α/β ratio, or perhaps another model altogether (e.g. 
involving repair kinetics, or daily dose level thresholds). 
As previously described for this data set [16], high-risk patients 
(Gleason 8) in the HF arm experienced significantly fewer local re-
currences than in the CF arm, even though there was no difference in 
overall failure free survival. This suggests that for a high-risk subgroup 
the HF scheme may be more effective to treat the primary tumor 
(receiving full dose prescription), but at the same time perhaps less 
effective at eradicating subclinical disease receiving intermediate levels 
of incidental dose. 
The main dose differences were found to overlap with the obturator 
internus muscles at a few centimeters away from the prostate, which is 
where the external beams have their field edges and therefore the largest 
dose gradients occur. Due to the strong spatial correlations in the dose 
distributions of external beams, the location of a large dose variation 
does not necessarily pin-point the location of an underlying mechanism. 
The identified regions were roughly consistent with previous findings 
[7], however these analyses concerned patients treated with 3DCRT 
techniques and larger margins, for which critical dose differences were 
located somewhat further away from the prostate. For the case where 
rectangular fields had superior tumor control compared to 3DCRT [8] 
the involved regions were located yet further away from the prostate. 
Our retrospective image analysis cannot prove the nature of a po-
tential underlying cause for the observed dose differences, however 
various observations may guide its hypothesis. The dose difference re-
gions seem to be too far away for extracapsular extensions as known 
from surgical series, which is usually observed to extend only a few 
millimeters outside the prostatic capsule, whereas radiotherapy prostate 
CTV delineations (on which the dose mapping was based) even tend to 
be rather wide around the actual organ to accommodate delineation 
uncertainties. Identified dose differences do extend towards the caudal 
part of the obturatorial lymph node region, however this region extends 
cranially on an ascending pathway toward the retroperitoneum [22] 
outside the reach of the radiation fields. It seems unlikely that occult 
lymph node metastasis only affected the most proximal stations for a 
large part of our study population [23]. Our results were evaluated at 
five years from randomization, and while this is a common timeframe 
for the primary endpoint of a clinical trial, development of the disease 
may span a much longer time. Lymph node metastases as may be imaged 
at treatment failure using PSMA PET-CT may occur years after RT, at 
which time the patient usually presents with many distant lesions 
simultaneously [24]. Interestingly, these authors also report a surpris-
ingly large fraction of patients (up to 15%) with lymph node recurrences 
in the mesorectum. This indicates that the disease must have had ample 
time to spread before leading to a PSA rise, and that this process would 
often involve the prostate’s local surroundings. This leaves open the 
question where the tumor cells that led to metastasis were located at the 
time of irradiation. While recurrent prostate carcinoma after RT is often 
found at the site of the primary tumor [25,26], this does not necessarily 
mean that distant metastases must have been seeded by a such local 
recurrence. Possibly, locally spread out tumor outside the high dose 
region could survive RT with less radiation damage than the cells 
receiving full dose inside the tumor, and despite lower numbers be 
quicker to metastasize; more so because spread out cells would consti-
tute a sub-population of tumor cells with a proven ability to invade 
surrounding tissues. Increased incidental dose levels to such regions 
could then lead to a delay in the process, resulting in a treatment failure 
difference after five years; it is not known whether these differences 
would remain significant at longer follow-up. The existence of isolated 
deposits (‘islets’) of tumor cells at a distance from the primary tumor has 
been studied in e.g. breast cancer [27] and NSCLC [28], however the 
spread of tumors within such organs may not easily translate to the 
spread of prostate carcinoma in the pelvis. In particular, the fact that 
dose difference regions mainly overlapped with obturator muscles 
complicates such an interpretation, as muscular tissues can resist a direct 
metastatic invasion quite well [29]. Considering that the main route for 
distant metastasis appears to be through blood vessels [30], perhaps 
invasion of the muscular vasculature plays a role, e.g. through the for-
mation of intra- or perivascular tumor micro-environments seeded by 
(clusters of) cancer cells which intravasate at the site of the primary 
tumor. Such micro-environments could aid in the further adaptation of 
cancer cells to acquire the traits necessary for successful extravasation at 
a distant site, and subsequent colony formation. The existence of such 
micro-environments outside the primary tumor site has however never 
been demonstrated. 
The results for the high-risk CF patients show positive dose differ-
ences at low q-values away from the prostate, but also regions of low q at 
the interface between prostate and rectum, for which dose differences 
are small but negative (see Fig. 1). In this region there is very little dose 
variation, which means that a given (small) dose difference easily attains 
a low q-value. In IMRT optimization an improved target conformity 
comes at the cost of increased complexity, and to reduce dose in one 
place it is generally necessary to allow dose increase elsewhere. Likely 
this is the cause of the observed cold region: plans with high PTV con-
formity towards the rectum required increased monitor units in the 
lateral beams which could then lead to the observed effects. 
As the underlying cause of observed dose differences is uncertain, we 
cannot currently advise to change the RT target for high risk patients in 
any particular way. However, based on current and previous findings we 
would suggest to incorporate dose delivery around the primary target 
when analyzing trial results, as such interactions going unnoticed may 
skew the analysis and obfuscate actual study results. If more studies can 
be shown to harbor similar effects, the combined body of evidence may 
help to formulate a sound hypothesis for a causal relation, and eventu-
ally enable prospective research to improve RT for these patients. 
The HYPRO data suggest an association between treatment failure 
and the incidental delivery of dose outside the prostate for high risk 
patients using conventional fractionation. The locations of identified 
dose differences may indicate local spread of subclinical disease in 
relevant tissues close to the prostate. 
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